Abstract:Objective To analyze the effect of anticoagulation with dabigatran etexilate on vascular function in patients with nonvalvular atrial fibrillation (NVAF). Methods The clinical data of 120 NVAF patients from June 2013 to June 2018 were analyzed retrospectively. According to the different treatment methods, they were divided into control group (rivaroxaban treatment) and observation group (dabigatran etexilate treatment). The clinical efficacy after treatment was observed and compared between two groups. Results After 12 weeks of treatment, the total effective rate in observation group was significantly higher than that in control group (93.33% vs 76.67%, P<0.05). There was no significant difference in liver function between the two groups before and after treatment (P>0.05). Compared with control group, the levels of endothelin-1 (ET-1), D-dimer, plasminogen activator (t-PA)and plasminogen activator inhibitor (PAI-1), decreased, while ankle brachial index(ABI), toe brachial index(TBI) increased in observation group (all P<0.05). The reaction time (R value), coagulation time (K value) and maximum amplitude of thrombus (MA value) in observation group were significantly higher than those in control group (all P<0.05), and the incidence of total adverse reactions was lower than that in control group (P<0.05). Conclusion For NVAF patients, anticoagulation therapy of dabigatran etexilate can improve the vascular function and reduce the incidence of complications with little effect on liver function and high safety.